• UPDATE : 2018.11.13 화 07:21
상단여백
기사 (전체 65건)
존 포티지 박사 "돌루테그라비르·라미부딘 2제 요법 단일정복합제, 기존 HIV 치료전략에 영향 하나의 옵션"
지난 17일 GSK의 HIV 전문기업인 비브 헬스케어(ViiV Healthcare)는 HIV-1 감염 치료를 위해 돌루테그라비르(DTG...
라인
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) announced resul...
라인
머크 바이오파마 앤드류 패터슨 수석부사장 "머크, 유럽 ECTRIMS서 발표 설문 연구 결과 등 통해 다발성경화증 간병인·환자들에게 더욱 효과적 도움 방안 찾을 수 있기 바란다”
독일 담슈타트 머크(Merck KGaA)는 독일 베를린에서 열린 제34차 유럽 다발성경화증 치료연구학회(ECTRIMS)에서 자사가 후원...
라인
유럽당뇨병학회서 리조덱 'Step by Step 임상 연구 결과' 공개…리조덱, 인슐린 글라진 U100+인슐린 아스파트 대비 '야간 저혈당 발생률' 감소
노보 노디스크는 1일부터 5일까지 독일 베를린에서 열리는 ‘제54회 유럽당뇨병학회(European Association for the ...
라인
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim today announced that it has acquired all shares of Vir...
라인
Strong start on underlying revenue and profitability led by Growth Drivers and Opex discipline
· Underlying Revenue grew +6.4%, led by Takeda's Growth Drivers(Gastroe...
라인
World Scleroderma Day 2018: Families open up about supporting a loved one with scleroderma, in new video series
Boehringer Ingelheim today reveals a new collection of unique, personal sto...
라인
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim announced a 230 million euro investment into a new Bio...
라인
Takeda Announces Term Loan Credit Agreement and Amendment to Bridge Credit Agreement in Connection with Proposed Shire Acquisition
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announces that...
라인
South Korea’s National Soccer Team Prepared 2018 Russia World Cup with Vaccination
Sanofi Pasteur in Korea(General Manager: Baptiste de Clarens) announced tha...
라인
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Family-owned pharmaceutical company Boehringer Ingelheim today presented it...
라인
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company fo...
라인
Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vac...
라인
Boehringer Ingelheim Starts New Campaign: 'Why wait in IPF?'
On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the quest...
라인
Takeda Announces Its Certification in Select Group of Global Top Employers 2018
Takeda Pharmaceutical Company Limited (TOKYO: 4502), (“Takeda”) today annou...
라인
Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announc...
라인
European Commission Approves ADCETRIS(brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy- Providing an Innovative Treatment Option to Patients
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
라인
Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to ...
라인
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc....
라인
AstraZeneca’s Calquence Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development cen...
Back to Top